Copy to clipboard 
Smith+Nephew reported 2Q25 orthopedic sales of $1 billion, up 6.4% compared to the second quarter of 2024. For the first half of 2025, the company generated $2 billion in orthopedic sales, up 3.8% compared to the prior period.
The company appears to be back on track, as it is steadily improving its orthopedic performance and has weathered the worst of the impact from volume-based procurement in China.
“I’ve talked a lot about our 12-Point Plan,” said Smith+Nephew CEO Deepak Nath. “We’re now in the final year of our three-year transformation that I first set out for you in July 2022. Each of the three parts of the 12-Point Plan is delivering great progress. The rewiring of our orthopedics business is well underway with sequential growth acceleration over the last four quarters at the global ortho, U.S. ortho and U.S. Recon and Robotics levels. Orthopedic inventory levels have improved, and we’ve seen the associated expected step-up in ortho margin.”
The company’s sustained improvement in joint replacement comes amid a commercial shift and portfolio rationalization for knee replacement implants. The commercial organization is refocusing its efforts on higher volume accounts. The company also plans to narrow down to two product families, LEGION and JOURNEY.
Elsewhere in its portfolio, Smith+Nephew got strong performances from the CATALYSTEM Hip System, AETOS shoulder, the EVOS plating system and its CORI robotic platform. In sports medicine, the company grew in double digits for knee, hip and shoulder repair with REGENETEN and Q-FIX KNOTLESS suture anchors being key drivers.
The company’s 2025 guidance remained unchanged, with underlying growth between 5% and 5.5%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $443.4 | $425.3 | $18.1 | 4.2% |
| Knees | $259.3 | $249.3 | $10.1 | 4% |
| Hips | $163.2 | $156.5 | $6.7 | 4.3% |
| Extremities | $20.9 | $19.6 | $1.3 | 6.6% |
| Trauma | $139.6 | $133.3 | $6.3 | 4.8% |
| Sports Medicine | $422.9 | $394.5 | $28.4 | 7.2% |
| Enabling Technology | $32.0 | $22.5 | $9.5 | 42.4% |
| Total | $1,037.9 | $975.6 | $62.3 | 6.4% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $861.7 | $847.7 | $14.0 | 1.7% |
| Knees | $506.0 | $497.1 | $8.9 | 1.8% |
| Hips | $314.0 | $311.6 | $2.3 | 0.8% |
| Extremities | $41.7 | $39.0 | $2.8 | 7.1% |
| Trauma | $273.3 | $260.3 | $12.9 | 5% |
| Sports Medicine | $816.3 | $787.3 | $29.0 | 3.7% |
| Enabling Technology | $58.0 | $40.5 | $17.5 | 43.3% |
| Total | $2,009.3 | $1,935.7 | $73.5 | 3.8% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $552.7 | $514.5 | $38.2 | 7.4% |
| OUS | $485.2 | $461.0 | $24.2 | 5.2% |
| EMEA | $265.4 | $245.1 | $20.3 | 8.3% |
| APAC | $95.4 | $93.9 | $1.5 | 1.6% |
| ROW | $124.4 | $122.0 | $2.3 | 1.9% |
| Total | $1,037.9 | $975.6 | $62.3 | 6.4% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,076.7 | $1,022.3 | $54.4 | 5.3% |
| OUS | $932.6 | $913.4 | $19.1 | 2.1% |
| EMEA | $526.3 | $501.2 | $25.1 | 5% |
| APAC | $175.7 | $182.0 | ($6.4) | (3.5%) |
| ROW | $230.6 | $230.2 | $0.4 | 0.2% |
| Total | $2,009.3 | $1,935.7 | $73.5 | 3.8% |
Smith+Nephew reported 2Q25 orthopedic sales of $1 billion, up 6.4% compared to the second quarter of 2024. For the first half of 2025, the company generated $2 billion in orthopedic sales, up 3.8% compared to the prior period.
The company appears to be back on track, as it is steadily improving its orthopedic performance and has weathered...
Smith+Nephew reported 2Q25 orthopedic sales of $1 billion, up 6.4% compared to the second quarter of 2024. For the first half of 2025, the company generated $2 billion in orthopedic sales, up 3.8% compared to the prior period.
The company appears to be back on track, as it is steadily improving its orthopedic performance and has weathered the worst of the impact from volume-based procurement in China.
“I’ve talked a lot about our 12-Point Plan,” said Smith+Nephew CEO Deepak Nath. “We’re now in the final year of our three-year transformation that I first set out for you in July 2022. Each of the three parts of the 12-Point Plan is delivering great progress. The rewiring of our orthopedics business is well underway with sequential growth acceleration over the last four quarters at the global ortho, U.S. ortho and U.S. Recon and Robotics levels. Orthopedic inventory levels have improved, and we’ve seen the associated expected step-up in ortho margin.”
The company’s sustained improvement in joint replacement comes amid a commercial shift and portfolio rationalization for knee replacement implants. The commercial organization is refocusing its efforts on higher volume accounts. The company also plans to narrow down to two product families, LEGION and JOURNEY.
Elsewhere in its portfolio, Smith+Nephew got strong performances from the CATALYSTEM Hip System, AETOS shoulder, the EVOS plating system and its CORI robotic platform. In sports medicine, the company grew in double digits for knee, hip and shoulder repair with REGENETEN and Q-FIX KNOTLESS suture anchors being key drivers.
The company’s 2025 guidance remained unchanged, with underlying growth between 5% and 5.5%.
Orthopedic Sales Data
Unless otherwise noted, all orthopedic sales data is provided in USD millions. We estimate orthopedic sales and growth rates on an as-reported basis.
Orthopedic Sales by Segment
| Segment | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $443.4 | $425.3 | $18.1 | 4.2% |
| Knees | $259.3 | $249.3 | $10.1 | 4% |
| Hips | $163.2 | $156.5 | $6.7 | 4.3% |
| Extremities | $20.9 | $19.6 | $1.3 | 6.6% |
| Trauma | $139.6 | $133.3 | $6.3 | 4.8% |
| Sports Medicine | $422.9 | $394.5 | $28.4 | 7.2% |
| Enabling Technology | $32.0 | $22.5 | $9.5 | 42.4% |
| Total | $1,037.9 | $975.6 | $62.3 | 6.4% |
| Segment | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| Joint Replacement | $861.7 | $847.7 | $14.0 | 1.7% |
| Knees | $506.0 | $497.1 | $8.9 | 1.8% |
| Hips | $314.0 | $311.6 | $2.3 | 0.8% |
| Extremities | $41.7 | $39.0 | $2.8 | 7.1% |
| Trauma | $273.3 | $260.3 | $12.9 | 5% |
| Sports Medicine | $816.3 | $787.3 | $29.0 | 3.7% |
| Enabling Technology | $58.0 | $40.5 | $17.5 | 43.3% |
| Total | $2,009.3 | $1,935.7 | $73.5 | 3.8% |
Orthopedic Sales by Geography
| Region | 2Q25 | 2Q24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $552.7 | $514.5 | $38.2 | 7.4% |
| OUS | $485.2 | $461.0 | $24.2 | 5.2% |
| EMEA | $265.4 | $245.1 | $20.3 | 8.3% |
| APAC | $95.4 | $93.9 | $1.5 | 1.6% |
| ROW | $124.4 | $122.0 | $2.3 | 1.9% |
| Total | $1,037.9 | $975.6 | $62.3 | 6.4% |
| Region | 1H25 | 1H24 | $ Chg | % Chg |
|---|---|---|---|---|
| US | $1,076.7 | $1,022.3 | $54.4 | 5.3% |
| OUS | $932.6 | $913.4 | $19.1 | 2.1% |
| EMEA | $526.3 | $501.2 | $25.1 | 5% |
| APAC | $175.7 | $182.0 | ($6.4) | (3.5%) |
| ROW | $230.6 | $230.2 | $0.4 | 0.2% |
| Total | $2,009.3 | $1,935.7 | $73.5 | 3.8% |
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
ME
Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.
